Press Room

Press Release / Oct 23, 2010

Aseptic Spray-Drying - Hovione’s latest offering

Loures, Portugal, 23rd October, 2009 - Hovione announced today that it has acquired an aseptic spray-drying production line, vial filling and back up utilities from Acusphere, a company located in Boston.

The equipment includes sterile filtration, aseptic spray drying, secondary drying and vial filling, as well as terminal sterilization systems, lyophilisation, WFI and clean steam production utilities. This acquisition is a great business opportunity, as it now provides Hovione access to equipment and knowhow for the production of sterile drug substance and sterile drug product.

“This is a very exciting move for Hovione, we are adding aseptic production -a tough new area of pharmaceutical manufacturing- to our offering. We have been considering aseptic production for some time and today we took the first step.” said Dave Hoffman, Head of Hovione’s Exclusives and Particle Design Business Units.

This acquisition adds to Hovione’s already impressive cGMP spray-drying facilities, which includes lab, pilot and various commercial scale production installations in Portugal, US and in Ireland. The range and versatility of the production equipment means Hovione can spray dry milligrams as well as deliver 400 tons/year from its Irish facility, spray drying HPAI’s (Highly Potent Active Ingredients) and now sterile compounds. Hovione’s in-house mathematical models, in combination with PAT and a QbD mindset, Hovione can solve the most complex solubility challenges.

About Hovione. Hovione is an international company dedicated to the cGMP development and manufacture of APIs and Intermediate Drug Products via particle design, serving exclusively the pharmaceutical industry. With four FDA inspected sites in the US, China, Ireland and Portugal, the company focuses on the most demanding projects, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For further information about Hovione, please visit the Hovione site at www.hovione.com or contact Corporate Communications (Isabel Pina, + 351 21 982 9362, e-mail: hello@hovione.com)

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026